Hear why Science Corp CEO Max Hodak says the screen era is ending at TechCrunch Disrupt 2026

Max Hodak, CEO of Science Corporation, will use a Disrupt stage session to argue that the coming era of computing may rely less on keyboards and screens and more on interfaces that connect directly to human biology. Hodak’s company is advancing that approach through brain-computer interface work and by recruiting a leading neurobiologist to run the first U.S. human trials of its biohybrid BCI.

Science Corporation already has clinical results in vision restoration. Its PRIMA retinal implant system, which pairs a tiny camera in a set of glasses with a chip implanted in the retina, has restored sight in people with severe vision loss. The company says its neural sensors could also support other medical uses, including detecting seizures, aiding recovery of damaged brain cells, and exploring treatments for disorders such as Parkinson’s disease.

Hodak’s career tracks the technology he’s promoting: early programming, a biomedical engineering degree from Duke’s Pratt School of Engineering, work in Miguel Nicolelis’ brain-computer interface lab, and leadership roles in startups including Transcriptic and Neuralink (which he co-founded in 2016 and served as initial president). He launched Science Corporation in 2021 to pursue neural engineering with a focus on vision, cognition and mobility.

Science Corporation has backed those ambitions with substantial funding; the company raised $230 million in a Series C round that valued it at $1.5 billion. Hodak’s Disrupt presentation will be aimed at the event’s community of entrepreneurs and investors, positioning screen-free interfaces as both a commercial and medical frontier.

TechCrunch Disrupt returns to Moscone West on October 13-15, 2026, with more than 250 sessions and an emphasis this year on building sustainable AI companies. Attendees who register before September 25 can save up to $200 on passes, and group registration discounts of up to 30% are available.